Related references
Note: Only part of the references are listed.Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study
Jong Yoon Lim et al.
ACTA OPHTHALMOLOGICA (2012)
Bevacizumab for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen: Clinical and Economic Impact
Gary Shienbaum et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
THREE-YEAR SAFETY AND VISUAL ACUITY RESULTS OF EPIMACULAR 90STRONTIUM/90YTTRIUM BRACHYTHERAPY WITH BEVACIZUMAB FOR THE TREATMENT OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Marcos P. Avila et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2012)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study
Frank G. Holz et al.
OPHTHALMOLOGY (2011)
The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2011)
ONE-YEAR OUTCOMES OF LESS FREQUENT BEVACIZUMAB IN AGE-RELATED MACULAR DEGENERATION
Kenan Sonmez et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2011)
ONE-YEAR RESULTS OF A FLEXIBLE REGIMEN WITH RANIBIZUMAB THERAPY IN MACULAR DEGENERATION Relationship with the Number of Injections
Luis Arias et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2011)
Radiation therapy for neovascular age-related macular degeneration
Robert Petrarca et al.
CLINICAL OPHTHALMOLOGY (2011)
Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2
Prema Abraham et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2010)
Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials
P. Mitchell et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2010)
Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration
Ciro Costagliola et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2010)
A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study
M. J. Potter et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2010)
Combination therapy in exudative age-related macular degeneration: visual outcomes following combined treatment with photodynamic therapy and intravitreal bevacizumab
Michael J. Wan et al.
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE (2010)
Let us wake the nation on the treatment for age-related macular degeneration
Gary Brown et al.
CURRENT OPINION IN OPHTHALMOLOGY (2010)
Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature
S. Jyothi et al.
EYE (2010)
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact
Omesh P. Gupta et al.
OPHTHALMOLOGY (2010)
ANATOMICAL BENEFIT FROM RANIBIZUMAB TREATMENT OF PREDOMINANTLY CLASSIC NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE 2-YEAR ANCHOR STUDY
Srinivas R. Sadda et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2010)
Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study
Adnan Tufail et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties
Alan F. Cruess et al.
ACTA OPHTHALMOLOGICA (2009)
Effects of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Attributable to Age-related Macular Degeneration
Simon P. Rothenbuehler et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)
A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
Geeta A. Lalwani et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)
Results of One-Year's Treatment with Ranibizumab for Exudative Age-related Macular Degeneration in a Clinical Setting
Salomon Y. Cohen et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)
Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration
M. P. Avila et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2009)
A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration
David S. Boyer et al.
OPHTHALMOLOGY (2009)
Evaluation of Injection Frequency and Visual Acuity Outcomes for Ranibizumab Monotherapy in Exudative Age-related Macular Degeneration
Hajir Dadgostar et al.
OPHTHALMOLOGY (2009)
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
David M. Brown et al.
OPHTHALMOLOGY (2009)
A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration
Quan Dong Nguyen et al.
OPHTHALMOLOGY (2009)
TWELVE-MONTH SAFETY AND VISUAL ACUITY RESULTS FROM A FEASIBILITY STUDY OF INTRAOCULAR, EPIRETINAL RADIATION THERAPY FOR THE TREATMENT OF SUBFOVEAL CNV SECONDARY TO AMD
Marcos P. Avila et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2009)
A prospective study on intravitreal bevacizumab (Avastin®) for neovascular age-related macular degeneration of different durations
Peep V. Algvere et al.
ACTA OPHTHALMOLOGICA (2008)
Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study
Ziad F. Bashshur et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
Carl D. Regillo et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study
G. Weigert et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2008)
Twelve-month safety of intravitreal injections of bevacizumab (Avastin (R)): results of the Pan-American Collaborative Retina Study Group (PACORES)
Lihteh Wu et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2008)
Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results
C. A. Cleary et al.
EYE (2008)
Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration
Peter K. Kaiser et al.
OPHTHALMOLOGY (2007)
Cigarette smoking and age-related macular degeneration in the EUREYE study
U. Chakravarthy et al.
OPHTHALMOLOGY (2007)
Intravitreal bevacizumab (avastin) treatment of neovascular age-related macular degeneration
M. Vaughn Emerson et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2007)
Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration
Eric Chen et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2007)
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: A short-term study
Christine Y. Chen et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2007)
Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments
Fabio Bom Aggio et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2007)
Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration
Ratimir Lazic et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2007)
Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration
Pradeepa Yoganathan et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2006)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration
Richard F. Spaide et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2006)
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration
RL Avery et al.
OPHTHALMOLOGY (2006)
Age-related macular degeneration: economic burden and value-based medicine analysis
MM Brown et al.
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE (2005)
Current concepts in the pathogenesis of age-related macular degeneration
MA Zarbin
ARCHIVES OF OPHTHALMOLOGY (2004)
Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor
U Schmidt-Erfurth et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Share Paper
